Harold E. Varmus
|14th Director of the National Cancer Institute|
|Preceded by||John E. Niederhuber|
|Succeeded by|| Douglas R. Lowy (Acting)|
|14thDirector of the National Institutes of Health|
November 23, 1993 –December 31, 1999
|Preceded by||Bernadine Healy|
|Succeeded by||Elias Zerhouni|
Harold Eliot Varmus
December 18, 1939
Oceanside, New York, US
Constance Louise Casey
Harold Eliot Varmus (born December 18, 1939) is an American Nobel Prize-winning scientist who was director of the National Institutes of Health from 1993 to 1999 and the 14th Director of the National Cancer Institute from 2010 to 2015, a post to which he was appointed by President Barack Obama.He was a co-recipient (along with J. Michael Bishop) of the 1989 Nobel Prize in Physiology or Medicine for discovery of the cellular origin of retroviral oncogenes. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center.
Varmus was born to Beatrice, a social service worker, and Frank Varmus, a physician, Jewish parents of Eastern European descent, in Oceanside, New York.In 1957, he graduated from Freeport High School in Freeport, New York, and enrolled at Amherst College, intending to follow in his father's footsteps as a medical doctor, but eventually graduating with a B.A. in English literature. He went on to earn a graduate degree in English at Harvard University in 1962 before changing his mind once again and applying to medical schools. He was twice rejected from Harvard Medical School. That same year, he entered the Columbia University College of Physicians and Surgeons and later worked at a missionary hospital in Bareilly, India, and the Columbia Presbyterian Medical Center. As an alternative to serving militarily in the Vietnam War, Varmus joined the Public Health Service at the National Institutes of Health in 1968. Working under Ira Pastan, he researched the regulation of bacterial gene expression by cyclic AMP. In 1970, he began postdoctoral research in Bishop's lab at University of California, San Francisco.
To fulfill his national service obligations during the Vietnam War, Varmus became a member of the commissioned corps of the Public Health Service, working as a Clinical Associate in the laboratory of Ira Pastan at the National Institutes of Health from 1968 to 1970. During this first period of laboratory research, he and Pastan and their colleagues described aspects of the mechanism by which the lac operon of E. coli is regulated transcriptionally by cyclic AMP.In 1970, he and his wife, Constance Casey, moved to San Francisco, where he began post-doctoral studies with Michael Bishop at University of California, San Francisco under a fellowship from the California Division of the American Cancer Society. Appointed as an assistant professor in the UCSF Department of Microbiology and Immunology in 1972, he was promoted to professor in 1979 and became an American Cancer Society Research Professor in 1984.
During the course of his years at UCSF (1970 to 1993), Varmus's scientific work was focused principally on the mechanisms by which retroviruses replicate, cause cancers in animals, and produce cancer-like changes in cultured cells. Much of this work was conducted jointly with Michael Bishop in a notably long scientific partnership. Their best-known accomplishmentwas the identification of a cellular gene (c-src) that gave rise to the v-src oncogene of Rous Sarcoma Virus, a cancer-causing virus first isolated from a chicken sarcoma by Peyton Rous in 1910. Their discovery triggered the identification of many other cellular proto-oncogenes—progenitors of viral oncogenes and targets for mutations that drive human cancers. Much of this work and its consequences are described in his Nobel lecture and Bishop's, in Varmus' book The Art and Politics of Science, and in numerous histories of cancer research.
Other significant components of Varmus's scientific work over the past four and a half decades include descriptions of the mechanisms by which retroviral DNA is synthesized and integrated into chromosomes;discovery of the Wnt-1 proto-oncogene with Roel Nusse; elucidation of aspects of the replication cycle of hepatitis B virus (with Donald Ganem ); discovery of ribosomal frameshifting to make retroviral proteins (with Tyler Jacks ); isolation of a cellular receptor for avian retroviruses (with John Young and Paul Bates ); characterization of mutations of the epidermal growth factor receptor gene in human lung cancers, including a common mutation that confers drug resistance (with William Pao ); and generation of numerous mouse models of human cancer. Notably, Varmus continued to conduct or direct laboratory work throughout his service in leadership positions at the NIH, MSKCC, and NCI.
In the early 1990s, following the award of their Nobel Prize, Varmus and Bishop became active in the politics of science, working principally with UCSF colleagues Bruce Alberts and Marc Kirschner, and with the Joint Steering Committee (later renamed the Coalition for the Life Sciences).He also co-chaired Scientists and Engineers for Clinton-Gore during the 1992 Presidential Campaign.
After the resignation of NIH Director Bernadine Healy in April, 1993, Varmus was nominated for the post by President William J. Clinton in July, and confirmed by the Senate in November. As the NIH director, Varmus was credited with helping to nearly double the research agency's budget; but his tenure was also noted for appointments of outstanding scientists to serve as Institute Directors; for excellent relationships with members of Congress and the Administration; for leadership on clinical and AIDS research; for policy statements about stem cell research, cloning of organisms, gene therapy, and patenting; for promoting global health research, especially on malaria; and for construction of new facilities, including a new Clinical Center and a Vaccine Research Center at the NIH.
Varmus supported the presidential candidacies of Al Gore (2000) and John Kerry (2004). During the George W. Bush presidency, he gave lectures critical of the Administration's science policies.But he has also written a laudatory account of PEPFAR (the President's Emergency Plan For AIDS Relief), Bush's initiative to combat AIDS globally.
Varmus declared his support for Barack Obama's quest for the presidency early in 2008and chaired the campaign's Science and Technology Committee. Following Obama's election, he was named by the president-elect as one of three co-chairs of PCAST (the President's Council of Advisors on Science and Technology). He resigned from that post to assume the directorship of the National Cancer Institute (NCI) on July 12, 2010, after being named to the post by President Obama.
On May 17, 2010, the White House announced that Varmus would become the 14th Director of the NCI, making him the first person to have served as director of an individual NIH Institute after being director of the entire NIH. In this capacity, despite diminishing budgets at all the Institutes including NCI, he started new administrative centers for cancer genomics and global health; initiated novel grant programs for "outstanding investigators," for "staff scientists," and for addressing "Provocative Questions."He also renamed the Frederick National Laboratory for Cancer Research and started an initiative there to study RAS oncogenes.
On March 4, 2015, Varmus submitted his resignation to the president, effective March 31, 2015, announcing his intention to return to New York City as the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and as a senior associate at the New York Genome Center.Deputy NCI Director Douglas Lowy became acting director of the NCI on April 1, 2015.
During his tenure as NCI Director, Varmus took the unusual step of co-authoring with three non-governmental colleagues a critique of several practices prevalent in the biomedical research community.That essay has been the starting point for several subsequent efforts to reduce the hypercompetitive atmosphere in biomedical research.
After leaving the NIH Directorship at the end of 1999, Varmus became the president and CEO of Memorial Sloan-Kettering Cancer Center in New York City on January 1, 2000. During his ten and a half years at MSKCC, he was best known for enlarging the basic and translational research faculty; building a major new laboratory facility, the Mortimer E. Zuckerman Research Center; starting a new graduate school for cancer biology (the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences); overseeing renovation and construction of many clinical facilities; and leading a major capital campaign.He also continued to run an active laboratory and to teach as a Member of the Sloan-Kettering Institute. On January 12, 2010, MSKCC reported that Varmus had asked the MSKCC Boards of Overseers and Managers "to begin a search for his successor." He left MSKCC on June 30, 2010, shortly before assuming the NCI directorship.
Near the end of his tenure as NIH director, Varmus became a champion of ways to more effectively use the Internet to enhance access to scientific papers.The first practical outcome was the establishment, with David Lipman of the National Center for Biotechnology Information at NIH, of PubMed Central, a public digital library of full-length scientific reports; in 2007, Congress directed NIH to ensure that all reports of work supported by the NIH appear in PubMed Central within a year after publication. Varmus and two colleagues, Patrick Brown at Stanford and Michael Eisen at UC Berkeley, were co-founders and leaders of the board of directors of the Public Library of Science (PLOS), a not-for-profit publisher of a suite of open access journals in the biomedical sciences.
Varmus has been a frequent advisor to the US government, foundations, academic institutions and industry. Currently, he serves as a member of the Secretary of Energy's advisory board, the Global Health Advisory Board at the Bill and Melinda Gates Foundation, the board of directors of the International Biomedical Research Alliance,the Lasker Foundation Prize Jury, and the Scientific Advisory Board of the Broad Institute at Harvard and MIT, and he chairs advisory groups for the Faculty of 1000 and the Global Alliance for Genomics and Health. In the past, he was chairman of the Grand Challenges in Global Health at the Gates Foundation, a member of the World Health Organization's Commission on Macroeconomics and Health, and an advisor to Merck & Co., Chiron Corporation, Gilead, and Onyx Pharmaceuticals.
Varmus has criticized the high cost of many modern cancer drugs, which create barriers to treatment. He advocates for the genetic testing of cancers as a routine reimbursed procedure, and for wider use of the information that genetic tsting of cancer can provide. He argues that widespread use of panel tests and exome analyses to identify cancer-causing mutations would be simpler and cheaper than full genome analysis. He has argued for the coverage of such services under Medicare and Medicaid on the grounds of Coverage with Evidence Development, since the data could be used to better evaluate test and treatments. He supports the creation of a database of information that can be correlated with clinical outcomes for use by all oncologists. He is hopeful that researchers will soon use new technologies to move beyond the study of primary tumors, where they have had considerable success, and explore how cancer initiates and the development of metastasic cancers.
Varmus has been married since 1969 to Constance Louise Casey, a journalist and science writer. They live on Manhattan's Upper West Side and have two sons: Jacob, a jazz trumpet player and composer who lives in Queens, and Christopher, a social worker who lives in Brooklyn. Varmus and Jacob have performed a series of lecture-concerts entitled "Genes and Jazz" at the Guggenheimand Smithsonian Museums, the Boston Museum of Science, the John F. Kennedy Center for the Performing Arts and the South Asian Summer Festival in Vancouver.
An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.
The University of California, San Francisco (UCSF) is a public land-grant research university in San Francisco, California. It is part of the University of California system and it is dedicated entirely to health science. It is a major center of medical and biological research and teaching.
The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. The majority of NIH facilities are located in Bethesda, Maryland and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through its Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.
Stanley Benjamin Prusiner is an American neurologist and biochemist. He is the director of the Institute for Neurodegenerative Diseases at University of California, San Francisco (UCSF). Prusiner discovered prions, a class of infectious self-reproducing pathogens primarily or solely composed of protein. He received the Albert Lasker Award for Basic Medical Research in 1994 and the Nobel Prize in Physiology or Medicine in 1997 for prion research developed by him and his team of experts beginning in the early 1970s.
Howard Martin Temin was an American geneticist and virologist. He discovered reverse transcriptase in the 1970s at the University of Wisconsin–Madison, for which he shared the 1975 Nobel Prize in Physiology or Medicine with Renato Dulbecco and David Baltimore.
John Michael Bishop is an American immunologist and microbiologist who shared the 1989 Nobel Prize in Physiology or Medicine with Harold E. Varmus and was co-winner of 1984 Alfred P. Sloan Prize. He serves as an active faculty member at the University of California, San Francisco (UCSF), where he also served as chancellor from 1998 to 2009.
Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is the largest and oldest private cancer center in the world, and is one of 51 National Cancer Institute–designated Comprehensive Cancer Centers. Memorial Sloan Kettering is affiliated with Cornell University's medical school. Its main campus is located at 1275 York Avenue, between 67th and 68th streets, in Manhattan.
Harvey James Alter is an American medical researcher, virologist, physician and Nobel Prize laureate, who is best known for his work that led to the discovery of the hepatitis C virus. Alter is the former chief of the infectious disease section and the associate director for research of the Department of Transfusion Medicine at the Warren Grant Magnuson Clinical Center in the National Institutes of Health (NIH) in Bethesda, Maryland. In the mid-1970s, Alter and his research team demonstrated that most post-transfusion hepatitis cases were not due to hepatitis A or hepatitis B viruses. Working independently, Alter and Edward Tabor, a scientist at the U.S. Food and Drug Administration, proved through transmission studies in chimpanzees that a new form of hepatitis, initially called "non-A, non-B hepatitis" caused the infections, and that the causative agent was probably a virus. This work eventually led to the discovery of the hepatitis C virus in 1988, for which he shared the Nobel Prize in Physiology or Medicine in 2020 along with Michael Houghton and Charles M. Rice.
The "war on cancer" is the effort to find a cure for cancer by increased research to improve the understanding of cancer biology and the development of more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death. The signing of the National Cancer Act of 1971 by United States president Richard Nixon is generally viewed as the beginning of this effort, though it was not described as a "war" in the legislation itself.
Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src, or simply c-Src, is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. It belongs to a family of Src family kinases and is similar to the v-Src gene of Rous sarcoma virus. It includes an SH2 domain, an SH3 domain and a tyrosine kinase domain. Two transcript variants encoding the same protein have been found for this gene.
Edison T. Liu, M.D., is the president and CEO of The Jackson Laboratory, and was the president of Human Genome Organization, HUGO from 2007-2013.
Francis Sellers Collins is an American physician-geneticist who discovered the genes associated with a number of diseases and led the Human Genome Project. He is director of the National Institutes of Health (NIH) in Bethesda, Maryland.
Peter K. Vogt is an American molecular biologist, virologist and geneticist. His research focuses on retroviruses and viral and cellular oncogenes.
Hidesaburo Hanafusa was a Japanese virologist. He shared the 1982 Albert Lasker Award for Basic Medical Research with Harold E. Varmus and J. Michael Bishop for demonstrating how RNA tumor viruses cause cancer, and elucidating their role in combining, rescuing and maintaining oncogenes in the viral genome.
Maurice Green was an American virologist whose research career spanned more than six decades. He is regarded as a pioneer in the study of animal viruses, in particular their role in cancer. Green founded the Institute of Molecular Virology at St. Louis University School of Medicine in the late 1950s, and later served as its chairman.
Douglas R. Lowy is the Acting Director of the U.S. National Cancer Institute (NCI) and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy previously served as Acting Director of NCI between April 2015-October 2017. On April 8, 2019, he again became Acting Director as Director Norman Sharpless transitioned to serve as the Acting Commissioner of the U.S. Food and Drug Administration. Lowy served as Deputy Director of the NCI since 2015, alongside former directors Harold E. Varmus and Sharpless. Lowy was co-recipient of the National Medal of Technology and Innovation in 2014 and the Lasker-DeBakey Clinical Medical Research Award in 2017.
The Frederick National Laboratory for Cancer Research (FNLCR) is a United States federally funded research and development center (FFRDC) supported by the National Cancer Institute and managed by the private contractor Leidos Biomedical Research. The institution was originally established under the name Frederick Cancer Research and Development Center in 1972 as a component of President Richard Nixon's War on Cancer initiative. In 2012, the institution received a national laboratory designation and assumed its current name, becoming the only U.S. national laboratory exclusively dedicated to biomedical research. The campus in Frederick, Maryland also houses National Cancer Institute laboratories and administrative organizations, and is colloquially referred to as NCI-Frederick.
George F. Vande Woude was a scientist and former director at Van Andel Research Institute in Michigan studying breast cancer.
Electron Kebebew, M.D., is an Ethiopian-born American surgeon, educator, scientist, academic leader, and health system administrator. Dr. Kebebew is the Harry A. Oberhelman Jr. and Mark L. Welton endowed Professor of Surgery at Stanford University. Starting in 2018, he continues to serve as Chief of General Surgery for Stanford Health Care. Kebebew is known internationally for his surgical skills and specializes in treating endocrine cancers, studying the treatment of rare and fatal endocrine tumors.
|Wikimedia Commons has media related to Harold E. Varmus .|
|14th Director of the National Institutes of Health |
1993 – 1999
John E. Niederhuber
|14th Director of the National Cancer Institute |
2010 – 2015
Douglas R. Lowy (Acting)